Aberrant activation-induced cytidine deaminase gene expression links BCR/ABL1-negative classical myeloproliferative neoplasms
Yükleniyor...
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
TR- Dizin
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Aim: Activation-induced cytidine deaminase (AID) has been associated with tumor initiation and development because of its ability to generate DNA damage and somatic mutations that cause genomic instability. This study aimed to investigate the relationship between AID expression levels and the risk of developing BCR/ABL1-negative myeloproliferative neoplasms (MPNs) by comparing the AID expression levels of the patients and controls. Methods: This case-control study was conducted on 117 cases (64 essential thrombocythemia, 23 primary myelofibrosis, and 30 polycythemia vera) with MPNs and 69 healthy controls. The JAK2 V617F somatic mutation analysis was performed using a real-time polymerase chain reaction (RT-PCR). The relative expression levels of AID in the patient and the control groups were analyzed using quantitative RT-PCR and the 2-??CT method. Results: AID expression levels were significantly higher in the patient group compared to the control group (p<0.001). AID expression levels were higher in patients with the JAK2 V617F mutation compared to patients without the mutation, but the difference was not statistically significant. Conclusion: The results of our study suggest that although overexpression of AID does not seem to support the JAK2 driver gene, it may contribute to the development of MPNs through other mechanisms.
Açıklama
Anahtar Kelimeler
Cytidine Deaminase, Mutations, Genomic Instability
Kaynak
Haseki Tıp Bülteni
WoS Q Değeri
N/A
Scopus Q Değeri
Q4
Cilt
60
Sayı
3
Künye
DERMENCİ H,ADAY A. D,TEKER A. B. A,HANÇER V,GELMEZ M. Y,NALÇACI M,YAVUZ A. S (2022). Aberrant Activation-Induced Cytidine Deaminase
Gene Expression Links BCR/ABL1-Negative Classical
Myeloproliferative Neoplasms. Haseki Tıp Bülteni, 60(3), 228 - 233. Doi: 10.4274/haseki.galenos.2022.8133
